For research use only. Not for therapeutic Use.
Danavorexton (TAK-925) is an orexin receptor agonist with brain permeability. Danavorexton induces a physiological pattern of OX2R activation in vitro to wake up sleepy mice and improve sleepiness symptoms[1][2][3][4].
Danavorexton (1, 10 mg/kg or 1, 3 mg/kg, subcutaneous injection) dose-dependent enhanced arousal in common marmosets and cynomolgus monkeys[2].
| Catalog Number | I025532 |
| CAS Number | 2114324-48-8 |
| Molecular Formula | C21H32N2O5S |
| Purity | ≥95% |
| Reference | [1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 34, No. 2, 2020. [2]. Evans R, et al. Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals. J Sleep Res. 2023 Oct;32(5):e13878 [3]. Ishikawa T, et al. Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model. Pharmacol Biochem Behav. 2022 Oct;220:173464. [4]. Fujimoto T, et al. Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist. ACS Med Chem Lett. 2022 Feb 4;13(3):457-462. |
